(Q74450922)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

The economics of febrile neutropenia: implications for the use of colony-stimulating factors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

G H Lyman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

N Kuderer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

J Greene

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

L Balducci

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 November 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

10 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

1857-1864

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

The national economic burden of cancer: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukaemic malignant disease. A randomised economic study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900222-6

7 January 2021

10.1016/S0959-8049(98)00222-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10023306%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference